Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma.
Abscopal effect
Antigens
Immunogenic cell death
Immunotherapy
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
01
04
2020
accepted:
20
09
2020
pubmed:
3
10
2020
medline:
31
3
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant lesions most likely mediated by an anti-tumor immune response. Although microwave ablation (MWA) is increasingly substituting other ablative techniques, its systemic immunostimulatory effects are poorly studied. We analyzed tumor-specific immune responses in peripheral blood of HCC patients after thermal ablation with regard to T cell responses and disease outcome. While comprehensive flow cytometric analyses in sequential samples of a prospective patient cohort (n = 23) demonstrated only moderate effects of MWA on circulating immune cell subsets, fluorospot analyses of specific T cell responses against seven tumor-associated antigens (TTAs) revealed de-novo or enhanced tumor-specific immune responses in 30% of patients. This anti-tumor immune response was related to tumor control as Interferon-y and Interleukin-5 T cell responses against TAAs were more frequent in patients with a long-time remission (> 1 year) after MWA (7/16) compared to patients suffering from an early relapse (0/13 patients) and presence of tumor-specific T cell response (IFN-y and/or IL-5) was associated to longer progression-free survival (27.5 vs. 10.0 months). Digital image analysis of immunohistochemically stained archival HCC samples (n = 18) of patients receiving combined MWA and resection revealed a superior disease-free survival of patients with high T cell abundance at the time of thermal ablation (37.4 vs. 13.1 months). Our data demonstrates remarkable immune-related effects of MWA in HCC patients and provides additional evidence for a combination of local ablation and immunotherapy in this challenging disease.
Identifiants
pubmed: 33006650
doi: 10.1007/s00262-020-02734-1
pii: 10.1007/s00262-020-02734-1
pmc: PMC7979675
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
893-907Références
Ferlay J, Ervik M, Lam F, et al (2018) Global Cancer Observatory, Cancer Today, estimated number of new cases in 2018, worldwide, both sexes, all ages. In: Glob. Cancer Obs. Cancer Today. Lyon, Fr. Int. Agency Res. Cancer. https://gco.iarc.fr/today . Accessed 30 Oct 2018.
Galle PR, Forner A, Llovet JM et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Herbold T, Wahba R, Bangard C et al (2012) The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma—indication, technique and results. Langenbeck’s Arch Surg 398:47–53
doi: 10.1007/s00423-012-1018-5
Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208
doi: 10.1038/nrc3672
Poulou LS, Botsa E, Thanou I et al (2015) Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 7:1054–1063
doi: 10.4254/wjh.v7.i8.1054
Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG (2003) Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of the primary tumor: an in situ tumor vaccine? J Urol 170:178–179
doi: 10.1097/01.ju.0000070823.38336.7b
Ahmad F, Gravante G, Bhardwaj N et al (2010) Renal effects of microwave ablation compared with radiofrequency, cryotherapy and surgical resection at different volumes of the liver treated. Liver Int 30:1305–1314
doi: 10.1111/j.1478-3231.2010.02290.x
Chen Z, Shen S, Peng B, Tao J (2009) Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperth 25:374–382
doi: 10.1080/02656730902976807
Haen SP, Gouttefangeas C, Schmidt D et al (2011) Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperon 16:495–504
doi: 10.1007/s12192-011-0261-y
Rai R, Richardson C, Flecknell P et al (2005) Study of apoptosis and heat shock protein (HSP) expression in hepatocytes following radiofrequency ablation (RFA). J Surg Res 129:147–151
doi: 10.1016/j.jss.2005.03.020
Mehta A, Oklu R, Sheth RA (2016) Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response? Gastroenterol Res Pract 2016:9251375
doi: 10.1155/2016/9251375
Ali MY, Grimm CF, Ritter M et al (2005) Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol 43:817–822
doi: 10.1016/j.jhep.2005.04.016
Dromi SA, Walsh MP, Herby S et al (2009) Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 251:58–66
doi: 10.1148/radiol.2511072175
Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931
doi: 10.1056/NEJMoa1112824
Zerbini A, Pilli M, Penna A et al (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66:1139–1146
doi: 10.1158/0008-5472.CAN-05-2244
Widenmeyer M, Shebzukhov Y, Haen SP et al (2011) Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer 128:2653–2662
doi: 10.1002/ijc.25601
Mizukoshi E, Yamashita T, Arai K et al (2013) Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57:1448–1457
doi: 10.1002/hep.26153
Dong BW, Zhang J, Liang P et al (2003) Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia 19:119–133
doi: 10.1080/0265673021000017154
Zhou Y, Xu X, Ding J et al (2018) Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther 14:40–45
doi: 10.4103/jcrt.JCRT_775_17
Zhang H, Hou X, Cai H, Zhuang X (2017) Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol 26:207–211
doi: 10.1080/13645706.2017.1286356
Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol 232:199–209
doi: 10.1002/path.4287
Mlecnik B, Van Den Eynde M, Bindea G et al (2018) Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst 110:97–108
doi: 10.1093/jnci/djx123
Sideras K, Bots SJ, Biermann K et al (2015) Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer 112:1911–1920
doi: 10.1038/bjc.2015.92
Flecken T, Schmidt N, Hild S et al (2014) Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59:1415–1426
doi: 10.1002/hep.26731
Flynn MJ, Sayed AA, Sharma R et al (2019) Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology 69:2258–2270
doi: 10.1002/hep.30337
Xu L, Huang Y, Tan L et al (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29:635–641
doi: 10.1016/j.intimp.2015.09.017
Helmink BA, Reddy SM, Gao J et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549–555
doi: 10.1038/s41586-019-1922-8
Wan YY (2010) Multi-tasking of helper T cells. Immunology 130:166–171
doi: 10.1111/j.1365-2567.2010.03289.x
Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67–72
doi: 10.1007/s00262-013-1490-y
Zacharakis N, Chinnasamy H, Black M et al (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24:724–730
doi: 10.1038/s41591-018-0040-8
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (80-) 318:1305–1309
Gabrielson A, Wu Y, Wang H et al (2016) Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res 4:419–430
doi: 10.1158/2326-6066.CIR-15-0110
Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-) 348:124–128
doi: 10.1126/science.aaa1348
Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JCJA (2018) Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front Oncol 8:1–17
doi: 10.3389/fonc.2018.00269
Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449–1458
doi: 10.1038/s41591-018-0101-z
Llosa NJ, Cruise M, Tam A et al (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43–51
doi: 10.1158/2159-8290.CD-14-0863
Aerts M, Benteyn D, Van Vlierberghe H et al (2016) Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 22:253–261
doi: 10.3748/wjg.v22.i1.253
Jenne CN, Kubes P (2013) Immune surveillance by the liver. Nat Immunol 14:996–1006
doi: 10.1038/ni.2691
El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502
doi: 10.1016/S0140-6736(17)31046-2
Sangro B, Gomez-Martin C, De La Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81–88
doi: 10.1016/j.jhep.2013.02.022
Duffy AG, Makarova-Rusher OV, Pratt D et al (2016) Tremelimumab: a monoclonal antibody against CTLA-4—In combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract ca. J Clin Oncol 34:4073–4073
doi: 10.1200/JCO.2016.34.15_suppl.4073